Anand Shah, MD is a nationally recognized physician leader and health policy expert who is an Operating Advisor to Clayton, Dubilier & Rice. He is on the board of directors of Hero, Adagio Therapeutics, Big Health, and M2Gen. Dr. Shah served as the Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration. Dr. Shah’s efforts have focused on bringing new technologies to market, redesigning health care delivery and economic incentives, and expanding competition and consumer choice. At FDA, Dr. Shah led consensus policy development for fit-for-purpose programs including pandemic recovery and preparedness, Advanced Manufacturing, digital health, and decentralized clinical trials. Dr. Shah represented FDA with top-level policy makers of the White House and Cabinet, Congress, and state and local governments.
He previously served in two senior leadership roles at the Centers for Medicare & Medicaid Services. As Senior Medical Advisor, he was the primary counselor for agency-wide policy related to medical and scientific innovation. As the Chief Medical Officer of the Center for Medicare & Medicaid Innovation, Dr. Shah led the clinical design of novel value-based payment and service delivery models including those for advanced primary care, specialty care, and prescription drugs.
Dr. Shah was chief resident during his radiation oncology residency at Columbia University. He concurrently earned his MD from the University of Pennsylvania and an MPH in health care management and policy from the Harvard School of Public Health. He also served as a Canada-U.S. Fulbright Scholar.